JP2016537408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537408A5 JP2016537408A5 JP2016551077A JP2016551077A JP2016537408A5 JP 2016537408 A5 JP2016537408 A5 JP 2016537408A5 JP 2016551077 A JP2016551077 A JP 2016551077A JP 2016551077 A JP2016551077 A JP 2016551077A JP 2016537408 A5 JP2016537408 A5 JP 2016537408A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- composition
- calcium phosphate
- amorphous magnesium
- substituted calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 210
- 239000000203 mixture Substances 0.000 claims description 156
- -1 magnesium-substituted calcium phosphate Chemical class 0.000 claims description 61
- 239000000126 substance Substances 0.000 claims description 40
- 239000002105 nanoparticle Substances 0.000 claims description 32
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 22
- 239000011777 magnesium Substances 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 20
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 15
- 239000001506 calcium phosphate Substances 0.000 claims description 15
- 235000011010 calcium phosphates Nutrition 0.000 claims description 15
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002441 X-ray diffraction Methods 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 5
- 108010013639 Peptidoglycan Proteins 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 210000005004 lymphoid follicle Anatomy 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 206010061958 Food Intolerance Diseases 0.000 claims description 2
- 206010016946 Food allergy Diseases 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000007997 Tricine buffer Substances 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000007998 bicine buffer Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 210000001986 peyer's patch Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1319548.2 | 2013-11-05 | ||
| GBGB1319548.2A GB201319548D0 (en) | 2013-11-05 | 2013-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| PCT/GB2014/053291 WO2015067939A1 (en) | 2013-11-05 | 2014-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019173127A Division JP2020073467A (ja) | 2013-11-05 | 2019-09-24 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016537408A JP2016537408A (ja) | 2016-12-01 |
| JP2016537408A5 true JP2016537408A5 (enExample) | 2017-11-02 |
Family
ID=49767709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551077A Pending JP2016537408A (ja) | 2013-11-05 | 2014-11-05 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
| JP2019173127A Withdrawn JP2020073467A (ja) | 2013-11-05 | 2019-09-24 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019173127A Withdrawn JP2020073467A (ja) | 2013-11-05 | 2019-09-24 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10596122B2 (enExample) |
| EP (1) | EP3065715B1 (enExample) |
| JP (2) | JP2016537408A (enExample) |
| KR (1) | KR20160079060A (enExample) |
| CN (1) | CN105722504A (enExample) |
| AU (1) | AU2014345334B2 (enExample) |
| BR (1) | BR112016009809A2 (enExample) |
| CA (1) | CA2929123A1 (enExample) |
| EA (1) | EA201690659A1 (enExample) |
| ES (1) | ES2761559T3 (enExample) |
| GB (1) | GB201319548D0 (enExample) |
| IL (1) | IL245380B (enExample) |
| MX (1) | MX367473B (enExample) |
| SG (2) | SG10201803562YA (enExample) |
| WO (1) | WO2015067939A1 (enExample) |
| ZA (1) | ZA201602906B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319548D0 (en) | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| FR3021045B1 (fr) * | 2014-05-16 | 2020-02-21 | Solvay Sa | Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation |
| KR101893110B1 (ko) * | 2016-07-27 | 2018-08-31 | 삼일제약 주식회사 | 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제 |
| EP3538659A4 (en) * | 2016-11-09 | 2020-07-15 | Engene, Inc. | INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1 |
| CN110573455A (zh) * | 2017-04-27 | 2019-12-13 | 武礼伟仁株式会社 | 羟基磷灰石、化妆品和食品及其生产方法 |
| WO2021003601A1 (zh) * | 2019-07-05 | 2021-01-14 | 广州中大医疗器械有限公司 | 一种新型可载药微球及其制备方法 |
| WO2021086252A1 (en) | 2019-10-30 | 2021-05-06 | Psilox Ab | Stabilized amorphous calcium magnesium phosphate particle compositions |
| CN116768175B (zh) * | 2023-07-01 | 2025-12-19 | 常州市第二人民医院 | 高稳定性生物活性无定形磷酸钙镁的制备方法及应用 |
| KR20260019884A (ko) * | 2024-08-02 | 2026-02-10 | 한국과학기술연구원 | 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법 |
| CN118929595A (zh) * | 2024-08-30 | 2024-11-12 | 昆明理工大学 | 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| US6541037B1 (en) | 1995-05-19 | 2003-04-01 | Etex Corporation | Delivery vehicle |
| EP1872798B1 (en) | 2005-04-06 | 2013-06-05 | Kabushiki Kaisha Sangi | Intestinal absorptive anti-tumor agent |
| EP2106217B1 (en) | 2006-12-12 | 2019-03-13 | Firmenich S.A. | Active ingredient delivery system with an amorphous metal salt as carrier |
| US20120128767A1 (en) * | 2008-05-01 | 2012-05-24 | Lee William W | Therapeutic calcium phosphate particles and methods of making and using same |
| GB201319548D0 (en) | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
-
2013
- 2013-11-05 GB GBGB1319548.2A patent/GB201319548D0/en not_active Ceased
-
2014
- 2014-11-05 ES ES14799845T patent/ES2761559T3/es active Active
- 2014-11-05 US US15/033,750 patent/US10596122B2/en not_active Expired - Fee Related
- 2014-11-05 MX MX2016005415A patent/MX367473B/es active IP Right Grant
- 2014-11-05 BR BR112016009809A patent/BR112016009809A2/pt not_active Application Discontinuation
- 2014-11-05 SG SG10201803562YA patent/SG10201803562YA/en unknown
- 2014-11-05 EA EA201690659A patent/EA201690659A1/ru unknown
- 2014-11-05 KR KR1020167014309A patent/KR20160079060A/ko not_active Ceased
- 2014-11-05 AU AU2014345334A patent/AU2014345334B2/en not_active Ceased
- 2014-11-05 SG SG11201603261PA patent/SG11201603261PA/en unknown
- 2014-11-05 WO PCT/GB2014/053291 patent/WO2015067939A1/en not_active Ceased
- 2014-11-05 CA CA2929123A patent/CA2929123A1/en not_active Abandoned
- 2014-11-05 JP JP2016551077A patent/JP2016537408A/ja active Pending
- 2014-11-05 EP EP14799845.4A patent/EP3065715B1/en not_active Not-in-force
- 2014-11-05 CN CN201480060734.7A patent/CN105722504A/zh active Pending
-
2016
- 2016-04-29 ZA ZA2016/02906A patent/ZA201602906B/en unknown
- 2016-05-01 IL IL245380A patent/IL245380B/en not_active IP Right Cessation
-
2019
- 2019-09-24 JP JP2019173127A patent/JP2020073467A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chew et al. | Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice | |
| AU2020267191B2 (en) | Polymeric bile acid nanocompositions targeting the pancreas and colon | |
| Han et al. | Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development | |
| JP5841708B2 (ja) | 表面被覆微粒子の医薬組成物 | |
| Doostmohammadi et al. | Hydrogels for peptide hormones delivery: therapeutic and tissue engineering applications | |
| RU2011115192A (ru) | Диетологическая поддержка иммунной системы во время противораковой терапии | |
| US11628208B2 (en) | System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins | |
| JP2020528744A5 (enExample) | ||
| BR112020003494A2 (pt) | composto, métodos para aumentar uma resposta imunossupressora, para tratar um distúrbio inflamatório, uma doença autoimune, doença do enxerto contra hospedeiro, infecção crônica e obesidade e para inibir ou reduzir a rejeição a um transplante, e, composição farmacêutica | |
| US10786558B2 (en) | Oral dissolving films | |
| JP2020073467A (ja) | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 | |
| JP2020513420A (ja) | 負の表面電荷を有するマイクロ粒子及びナノ粒子 | |
| EP3220913B1 (en) | Nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies | |
| Okay et al. | Nanoparticle-based delivery platforms for mRNA vaccine development | |
| CN110769862B (zh) | 包含脂肽(lp)化合物的非病毒基因递送剂 | |
| Hanafi et al. | Cellulose acetate phthalate microencapsulation and delivery of plasmid DNA to the intestines | |
| Thirumalaikumar et al. | DNA vaccine incorporated poly (lactic-co-glycolic) acid (PLGA) microspheres offer enhanced protection against Aeromonas hydrophila infection | |
| Wang et al. | Oral biomimetic virus vaccine hydrogel for robust abscopal antitumour efficacy | |
| US10849962B2 (en) | Method and apparatus for microneedle transdermal delivery | |
| JP3492671B2 (ja) | 免疫アジュバント | |
| CN120053391A (zh) | 一种基于微囊的疫苗 | |
| WO2023219502A1 (en) | Immunotherapeutic compositions and adjuvants | |
| WO2024233809A2 (en) | Extracellular vesicle compositions and preparation | |
| TW202220974A (zh) | 用於調節ａｋｔ３的方法及組合物 | |
| Nayak et al. | Formulation and characterization of Chitosan coated PLA/PLGA encapsulated microparticles for vaccine development |